Black Diamond Therapeutics Inc. (BDTX) Next Earnings Date & Expected ±12.5% Move

Per the Roarable RQD rating, BDTX scores 59 out of 100, a letter grade of C-, with the verdict "Roarable Hold — Cautious Neutral." The five pillars are:

• Fundamental Cash Engine: 10 / 20. The rating cites ROIC of 10.8% and an FCF yield of 0%. The reported free cash flow of $29.6M for FY 2025 does not translate into a positive FCF yield in the rating's calculation, which is a point an investor should reconcile before relying on this pillar.
• Whale 13F Flow: 12 / 20. The rating labels this pillar as institutional accumulation and options positioning. The holders section contains no 13F data, so the score cannot be traced to specific filings within this source set.
• Insider Conviction: 9 / 20. The rating references SEC Form 4 and Congressional PTR cluster flow. No Form 4 or PTR records appear in the holders section, so this score is not independently verifiable here.
• Macro Regime Fit: 15 / 20. The rating cites a beta of 1.0 and sector sensitivity. This is the strongest pillar, indicating the rating treats the stock's market sensitivity as moderate rather than extreme.
• Forensic Balance Sheet: 13 / 20. The rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 5/9, and a Debt/Equity ratio of 0.5. These are mid-range readings that support a cautious, not distressed, assessment.

For a prospective investor, the rating's message is that the business is not yet generating clearly positive returns on a cash-yield basis, the balance sheet is serviceable rather than strong, and the stock's risk profile is moderate. The upside case depends on the cash-generation improvement visible in the FY 2025 figures continuing, while the valuation tradeoff is that the company has no reported revenue and a market capitalization of $106.9M, leaving the valuation highly sensitive to near-term cash and operating trajectory. The rating's "Hold" verdict reflects balance between these factors rather than a directional call.

Per the SEC financials, operating income moved from $-86.5M in FY 2023 to $-78.8M in FY 2024 and to $12.5M in FY 2025, and FCF moved from $-66.7M to $-62.3M to $29.6M over the same periods. Gross, operating, and net margins are each reported as 0% in the market data, which is consistent with zero reported revenue. Per the market data, ROIC is 10.8%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 5/9, and Debt/Equity is 0.5. The FY 2025 net income figure of $22367.0M is far out of line with the $12.5M operating income and is not explained in the source data; it should be verified against the filing before being relied upon.

Per the recent news feed, six items are tagged to BDTX, each classed YELLOW under the MARKET WIRE impact label. The headlines are generic market-coverage pieces from StockInvest.us, ChartMill, Yahoo Finance UK, Moomoo, Simply Wall St, and Yahoo! Finance Canada, covering price forecasts, options chains, seasonal return charts, and cash burn commentary. None describes a specific clinical, regulatory, or transactional event. The Simply Wall St item is headlined as a cash-burn assessment, which is the only headline bearing directly on the company's financial position. Per the butterfly supply-chain graph, there are no supply-chain links and no proprietary signals.

• What is the source of the $22367.0M FY 2025 net income figure, given operating income of $12.5M, and does it reflect a one-time item?
• What clinical, regulatory, or partnering milestones are expected, and when?
• What is the company's debt position, since the debt field is N/A across all periods while Debt/Equity is reported as 0.5?
• Why is EPS reported as N/A for every period, and what is the share count?
• What institutional or insider ownership exists, given the holders section is empty?